The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Open accessAbstract
Immunotherapy Packs a One-Two Punch: Despite the immune system's best efforts, cancer always seems to be one step ahead. One example of this is that tumor cells express CD47 on their cell surface. CD47 acts as a “don't eat me” signal to phagocytic macrophages. A potential therapeutic strategy could thus be to block this signal. Weiskopf et al. (p. 88 , published online 30 May; see the Perspective by Kershaw and Smyth ) created variants of the CD47 receptor, SIRPα, that could act as high-affinity antagonists of CD47. Although the antagonists blocked CD47 effectively in tumor-bearing mice, on their own they did not induce macrophages to phagocytose the tumor cells. When paired with a variety of therapeutic antitumor antibodies, however, the CD47 antagonists were very effective in treating several mouse tumor models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Apoptotic cell clearance: basic biology and therapeutic potential
Poon, I. K. H., Lucas, C. D., Rossi, A. G., & Ravichandran, K. S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3607 · Cited by 1,223
Apoptosis and Clearance of Apoptotic Cells
Nagata, S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053010 · Cited by 1,103
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Self-citationThe clearance of dead cells by efferocytosis
Boada-Romero, E., Martinez, J., Heckmann, B. L., & Green, D. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0232-1 · Cited by 876
Barclay, A. N., & van den Berg, T. K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120142 · Cited by 841
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H., Peng, H., Fu, Y.-X., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 767
Tumor metastasis: moving new biological insights into the clinic
Wan, L., Pantel, K., & Kang, Y. (2013) · Nature Medicine · doi:10.1038/nm.3391 · Cited by 748
The CD47-SIRPα Immune Checkpoint
Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 735
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683
Self-citationTumor-Associated Macrophages: Recent Insights and Therapies
Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., & Zhou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00188 · Cited by 619
Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., George, B. M., Markovic, M., Ring, N. G., Tsai, J. M., et al. (2018) · Nature Immunology · doi:10.1038/s41590-017-0004-z · Cited by 558
Self-citationThe CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
Yeast surface display platform for rapid discovery of conformationally selective nanobodies
McMahon, C., Baier, A. S., Pascolutti, R., Wegrecki, M., Zheng, S., Ong, J. X., Erlandson, S. C., Hilger, D., Rasmussen, S. G. F., Ring, A. M., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0028-6 · Cited by 546
Self-citationOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
“Moreover, targeting the CD47-SIRP a axis has now been shown to increase efficacy of several therapeutic antibodies.(42,43) CD47 is described to be highly expressed on CD38C MM cells,(44) suggesting that inhibition of the CD47-SIRP a axis might be an interesting therapeutic approach in combination with DARA.”
BackgroundSIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
Veillette, A., & Chen, J. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.12.005 · Cited by 476
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444
Self-citationGholamin, S., Mitra, S. S., Feroze, A. H., Liu, J., Kahn, S. A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2968 · Cited by 426
Self-citationTumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu, S.-Q., Waaijer, S. J. H., Zwager, M. C., de Vries, E. G. E., van der Vegt, B., & Schröder, C. P. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.010 · Cited by 425
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Matlung, H. L., Babes, L., Zhao, X. W., van Houdt, M., Treffers, L. W., van Rees, D. J., Franke, K., Schornagel, K., Verkuijlen, P., Janssen, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.082 · Cited by 403
Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy
Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506225 · Cited by 397
Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology
Morioka, S., Maueröder, C., & Ravichandran, K. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.018 · Cited by 391
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
Rao, L., Wu, L., Liu, Z., Tian, R., Yu, G., Zhou, Z., Yang, K., Xiong, H.-G., Zhang, A., Yu, G.-T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18626-y · Cited by 376
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
Self-citationEngineering growth factors for regenerative medicine applications
Mitchell, A. C., Briquez, P. S., Hubbell, J. A., & Cochran, J. R. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.11.007 · Cited by 372
Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis
Koh, E., Lee, E. J., Nam, G.-H., Hong, Y., Cho, E., Yang, Y., & Kim, I.-S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.004 · Cited by 365
Harnessing tumor‐associated macrophages as aids for cancer immunotherapy
Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364
Cancer immunotherapy targeting the CD47/SIRPα axis
Weiskopf, K. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.013 · Cited by 353
Self-citationAdvances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Zhang, W., Huang, Q., Xiao, W., Zhao, Y., Pi, J., Xu, H., Zhao, H., Xu, J., Evans, C. E., & Jin, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00018 · Cited by 353
Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330
Self-citationThe immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Liu, M., O’Connor, R. S., Trefely, S., Graham, K., Snyder, N. W., & Beatty, G. L. (2019) · Nature Immunology · doi:10.1038/s41590-018-0292-y · Cited by 294
Macrophages are critical effectors of antibody therapies for cancer
Weiskopf, K., & Weissman, I. L. (2015) · mAbs · doi:10.1080/19420862.2015.1011450 · Cited by 292
Self-citationThe role of efferocytosis in atherosclerosis
Kojima, Y., Weissman, I. L., & Leeper, N. J. (2017) · Circulation · doi:10.1161/circulationaha.116.025684 · Cited by 289
Self-citationFlores, A. M., Hosseini-Nassab, N., Jarr, K.-U., Ye, J., Zhu, X., Wirka, R., Koh, A. L., Tsantilas, P., Wang, Y., Nanda, V., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-019-0619-3 · Cited by 285
Self-citationAnti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., Shan, L., Volkmer, J.-P., George, B. M., Lietzenmayer, M., McKenna, K. M., Naik, T. J., McCarty, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710877114 · Cited by 283
Self-citationActivating Macrophage‐Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles
Rao, L., Zhao, S., Wen, C., Tian, R., Lin, L., Cai, B., Sun, Y., Kang, F., Yang, Z., He, L., et al. (2020) · Advanced Materials · doi:10.1002/adma.202004853 · Cited by 279
Petrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1700 · Cited by 278
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Bone Pain in Cancer Patients: Mechanisms and Current Treatment
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236047 · Cited by 262
Qie, Y., Yuan, H., von Roemeling, C. A., Chen, Y., Liu, X., Shih, K. D., Knight, J. A., Tun, H. W., Wharen, R. E., Jiang, W., et al. (2016) · Scientific Reports · doi:10.1038/srep26269 · Cited by 260
Extracellular vesicles as a platform for membrane‐associated therapeutic protein delivery
Yang, Y., Hong, Y., Cho, E., Kim, G. B., & Kim, I. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1440131 · Cited by 258
Lecoultre, M., Dutoit, V., & Walker, P. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001408 · Cited by 223
Efferocytosis in the tumor microenvironment
Werfel, T. A., & Cook, R. S. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0698-5 · Cited by 156
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
Kojima, Y., Downing, K., Kundu, R., Miller, C., Dewey, F., Lancero, H., Raaz, U., Perisic, L., Hedin, U., Schadt, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70391 · Cited by 148
Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“As of writing, the most advanced fusion products developed are TTI621 (69), TTI-622 (70), and ALX-148, previously known as CV1 (60, 61).”
BackgroundMartins, T. A., Kaymak, D., Tatari, N., Gerster, F., Hogan, S., Ritz, M.-F., Sabatino, V., Wieboldt, R., Bartoszek, E. M., McDaid, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54129-w · Cited by 54
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling
Nuvolone, M., Paolucci, M., Sorce, S., Kana, V., Moos, R., Matozaki, T., & Aguzzi, A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177876 · Cited by 13
Martins, T. A., Tatari, N., Kaymak, D., Hogan, S., Bartoszek, E. M., Wieboldt, R., Ritz, M.-F., Buck, A., McDaid, M., Gerber, A., et al. (2023) · doi:10.1101/2023.08.31.555122
Metadata
- Authors
- Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., & Garcia, K. C.
- Venue
- Science
- Published
- 2013-07-05
- Volume
- 341
- Issue
- 6141
- Pages
- 88-91
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2068052762
- Cited by
- 495
- References
- 38
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.